MSN Laboratories Pvt. Ltd. urged the Federal Circuit to reconsider a three-judge panel’s January ruling that revived a patent for Novartis AG’s blockbuster heart-disease drug Entresto. The Jan. 10 ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, its chief executive ...

Novartis (NVS) CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if its main focus remains on therapeutic areas where it ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of ...

NEW YORK – During a call Friday to discuss Novartis' fourth quarter and full-year 2024 financial results, executives boasted that the company last year delivered "one of the strongest performances" in ...

Because the proposed generic drug accused of infringement was a “complex” of bonded valsartan and sacubitril, the patentee Novartis needed to urge and had successfully urged that ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The company’s earnings surpassed estimates in each of the trailing four ...

Novartis, an innovative medicines company, announced that the company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that ...